CDBT: AI 评分 38/100 — AI 分析 (4月 2026)

China Dasheng Biotechnology Company operates in the financial services sector, focusing on shell company activities. The company, based in Lanzhou, China, produces and distributes bacteria-based products for livestock feed and crop cultivation.

Key Facts: AI Score: 38/100 Sector: Financial Services

公司概况

概要：

China Dasheng Biotechnology Company, operating within the financial services sector as a shell company, focuses on the production and distribution of bacteria-based additives for livestock feed and crop cultivation in China. The company offers biological bacterium blends and preservatives, serving agricultural and livestock markets.

CDBT是做什么的？

China Dasheng Biotechnology Company, formerly known as Max Nutrition, Inc., changed its name in March 2008 and is based in Lanzhou, China. The company, along with its subsidiaries, produces, markets, and distributes bacteria-based products used as additives for livestock feed and crop cultivation within the People's Republic of China. Their product line includes artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends, as well as biological preservatives. These products are designed to enhance soil quality, improve nutrient absorption, and reduce diseases in both crops and livestock. Specifically, the company provides AM/HM bacteria-based additives for crops, incorporating components like Bulgaria lactobacillus and beer microzyme. For livestock, the additives soften feed, restrain pathogenic bacteria, and supply beneficial nutrients. Additionally, China Dasheng Biotechnology Company offers FGW bacterial-based preservatives, used for preserving animal specimens and maintaining the freshness of agricultural produce. They also provide bacteria-based fertilizer for plants. The company also engages in residential and commercial real estate investment.

CDBT的投资论点是什么？

China Dasheng Biotechnology Company's investment thesis hinges on its niche market in bacteria-based agricultural additives within China. With a negative P/E ratio of -7.14, the company's profitability is a concern. Key value drivers include expanding its product line and increasing market penetration in the agricultural sector. Growth catalysts involve leveraging its existing distribution network and capitalizing on the demand for sustainable agricultural practices. However, potential risks include the company's OTC listing, which implies lower liquidity and higher volatility, as reflected by its beta of 2.26. Further, the absence of dividends may deter income-seeking investors.

CDBT在哪个行业运营？

China Dasheng Biotechnology Company operates within the agricultural biotechnology sector, which is influenced by trends towards sustainable farming and increasing demand for higher crop yields. The competitive landscape includes companies offering similar biological additives and fertilizers. The market is driven by the need for environmentally friendly solutions and the growing awareness of soil health. China's agricultural sector is a significant market, but competition is intense with both domestic and international players vying for market share.

Shell Companies

Financial Services

CDBT有哪些增长机遇？

Expansion into organic farming markets: The growing demand for organic produce presents an opportunity for China Dasheng Biotechnology Company to tailor its products for organic farming practices. The global organic food market is projected to reach $323.1 billion by 2024, offering a substantial market for specialized bacteria-based additives. This expansion could involve developing certifications and formulations that meet organic standards, enhancing market access and brand reputation.
Development of specialized livestock feed additives: Focusing on developing specialized additives for specific livestock needs, such as poultry or swine, can create a competitive advantage. The global animal feed additives market is projected to reach $27.9 billion by 2027. Tailoring products to address specific nutritional deficiencies or health concerns in livestock can increase product value and customer loyalty.
Geographic expansion within China: Expanding distribution networks to reach underserved regions within China can significantly increase market penetration. China's agricultural sector is vast and diverse, with varying needs across different provinces. Establishing partnerships with local distributors and agricultural cooperatives can facilitate market entry and build brand awareness in new regions. This targeted approach can capitalize on regional agricultural strengths and address specific local needs.
Research and development of novel bacterial strains: Investing in research and development to discover and commercialize novel bacterial strains with enhanced efficacy can drive product innovation. The agricultural biotechnology sector is constantly evolving, with new discoveries leading to improved crop yields and disease resistance. Developing proprietary bacterial strains can create a competitive edge and protect market share through patents and intellectual property.
Strategic partnerships with agricultural technology companies: Collaborating with agricultural technology companies to integrate bacteria-based additives into broader agricultural solutions can enhance market reach and product value. This could involve partnerships with companies specializing in precision farming, data analytics, or irrigation systems. Integrating biological additives into these technologies can create synergistic benefits and provide comprehensive solutions for farmers.

Operates in the financial services sector as a shell company.
Specializes in bacteria-based products for livestock feed and crop cultivation.
Based in Lanzhou, China, serving the People's Republic of China market.
P/E ratio of -7.14 indicates current lack of profitability.
Beta of 2.26 suggests high volatility compared to the market.

CDBT提供哪些产品和服务？

Produces bacteria-based additives for livestock feed.
Manufactures bacteria-based additives for crop cultivation.
Offers artificial microorganism (AM) based products.
Provides high-efficiency microorganism (HM) based products.
Distributes biological bacterium blends.
Supplies biological preservatives.
Engages in residential and commercial real estate investment.

CDBT如何赚钱？

Sells bacteria-based additives directly to farmers and agricultural businesses.
Distributes products through a network of distributors and retailers.
Generates revenue from the sale of biological preservatives.
Derives income from real estate investments.

Farmers cultivating various crops.
Livestock producers raising animals for meat and dairy.
Agricultural businesses involved in crop and livestock production.
Scientific research institutions requiring animal specimen preservation.
Real estate tenants (residential and commercial).

Proprietary bacteria strains and formulations.
Established distribution network within China.
Specialized knowledge in bacteria-based agricultural additives.
Brand recognition in the Chinese agricultural market.

什么因素可能推动CDBT股价上涨？

Upcoming: Potential expansion into new geographic markets within China.
Upcoming: Development and launch of new bacteria-based product lines.
Ongoing: Increasing demand for sustainable agricultural practices.
Ongoing: Growing awareness of soil health and the benefits of biological additives.

CDBT的主要风险是什么？

Potential: Limited financial disclosure due to OTC listing.
Potential: Lower liquidity and higher price volatility.
Ongoing: Competition from established agricultural companies.
Potential: Changes in agricultural regulations and policies.
Ongoing: Dependence on the agricultural sector, which can be cyclical.

CDBT的核心优势是什么？

Specialized in bacteria-based agricultural additives.
Established presence in the Chinese market.
Offers a range of products for both crop and livestock applications.
Engages in real estate investment for diversification.

CDBT的劣势是什么？

Negative P/E ratio indicates lack of profitability.
OTC listing suggests higher risk and lower liquidity.
Limited geographic diversification outside of China.
Dependence on the agricultural sector, which can be cyclical.

CDBT有哪些机遇？

Expansion into organic farming markets.
Development of specialized livestock feed additives.
Geographic expansion within China.
Strategic partnerships with agricultural technology companies.

CDBT面临哪些威胁？

Competition from established agricultural companies.
Changes in agricultural regulations and policies.
Economic downturns affecting the agricultural sector.
Potential for product liability claims.

CDBT的竞争对手是谁？

Assembly Biosciences Inc — Focuses on developing novel therapies for viral diseases. — (ASNB)
Eat Beyond Global Holdings Inc — Invests in the plant-based and alternative protein sector. — (EATBF)
Engage Mobility Inc — Provides mobile engagement solutions. — (ENGA)
Ezra Resources Inc — Operates in the natural resource sector. — (EZRG)
Family Doctor Clinic Inc — Operates healthcare clinics. — (FDOC)

Key Metrics

MoonshotScore: 38/100

Company Profile

CEO: Gang Chen
Headquarters: Lanzhou, CN
Employees: 689
Founded: 2008

AI Insight

AI analysis pending for CDBT

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does China Dasheng Biotechnology Company do?

China Dasheng Biotechnology Company produces and distributes bacteria-based products used as additives for livestock feed and crop cultivation in China. The company offers artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends, as well as biological preservatives. These products are designed to enhance soil quality, improve nutrient absorption, and reduce diseases in both crops and livestock. Additionally, the company engages in residential and commercial real estate investment.

What do analysts say about CDBT stock?

AI analysis is currently pending for CDBT. Given its OTC listing and limited financial information, a comprehensive analyst consensus is not readily available. Key valuation metrics such as P/E ratio (-7.14) indicate current challenges with profitability. Growth considerations include the company's ability to expand its market share in the Chinese agricultural sector and capitalize on the demand for sustainable farming practices. However, the OTC listing presents inherent risks related to liquidity and disclosure.

What are the main risks for CDBT?

The main risks for China Dasheng Biotechnology Company include its OTC listing, which implies lower liquidity and higher volatility. The limited financial disclosure associated with OTC-listed companies increases the risk for investors. Competition from established agricultural companies and potential changes in agricultural regulations also pose challenges. Additionally, the company's dependence on the agricultural sector makes it vulnerable to economic downturns and cyclical fluctuations.